SANOFI Patent applications |
Patent application number | Title | Published |
20160137627 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF - The invention relates to compounds corresponding to formula (I), in the form of the base or of an acid-addition salt: | 05-19-2016 |
20160082196 | AUTOMATIC DRUG INJECTION DEVICE WITH REVERSE WOUND FLAT SPIRAL SPRING DRIVE MECHANISM - The present invention relates to a handheld automatic injection device comprising a housing ( | 03-24-2016 |
20160074588 | Injection Device - The invention refers to a handheld injection device comprising a housing ( | 03-17-2016 |
20160067420 | DISPENSING SPEED CONTROL MECHANISM AND INJECTION DEVICE - The present invention relates to a dispensing speed control mechanism for use in an injection device. The injection device may have a housing ( | 03-10-2016 |
20160058949 | Drive Mechanism for a Drug Delivery Device - The present invention relates to a drive mechanism of a drug delivery device for setting and dispensing of a dose of a medicament, the mechanism comprising: a housing ( | 03-03-2016 |
20160051769 | Injection Device - The invention refers to an injection device comprising a housing ( | 02-25-2016 |
20160051768 | Injection Device - The invention refers to an injection device comprising a housing ( | 02-25-2016 |
20160045673 | HAND-HELD DRUG INJECTION DEVICE AND DOSE SETTING LIMITER MECHANISM THEREFOR - The present invention relates to a drive mechanism of a drug delivery device for dispensing of a dose of a medicament, the mechanism comprising: —a housing ( | 02-18-2016 |
20160024097 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, | 01-28-2016 |
20160016928 | Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals - The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them. | 01-21-2016 |
20160002316 | SERPINS: METHODS OF THERAPEUTIC BETA-CELL REGENERATION AND FUNCTION - Compositions and methods of use are provided for improving β cell function and promoting pancreatic β cell proliferation in vitro, in vivo and ex vivo. The active agents of the pending invention comprise Serpin family peptides (e.g., SerpinB1), functional and structural analogs of Serpin family peptides and nucleic acids encoding Serpin family peptides, as well as active fragments thereof. | 01-07-2016 |
20150374622 | CHEWABLE COMPOSITION FOR ORAL ADMINISTRATION AND PROCESS FOR PREPARING THEREOF - The present invention relates to chewable compositions for oral administration, said compositions comprising high(methyl)pectin, glycerol and water. Advantageously, the chewable composition can comprise a drug substance. The present invention also concerns a process for preparing the chewable composition and the use of said chewable composition as a medicament. | 12-31-2015 |
20150291536 | METHOD FOR PREPARING PHENYLOXYMETHYL-NITRO-IMIDAZOLE DERIVATIVES AND USE OF SAME - Fexinidazole is prepared according to a method which comprises the following steps: a) reacting 1-methyl-2-hydroxymethyl-5-nitro-imidazole with methanesulfonyl chloride in the presence of a suspension of powdered alkaline carbonate in an anhydrous organic solvent suitable for performing nucleophile substitution reactions; b) adding to the resulting reaction medium a solution of 4-methyl-mercapto-phenol in the same organic solvent as referred to in step a); c) separating fexinidazole from the reaction mixture as its hydrochloride salt and d) converting said hydrochloride salt into fexinidazole and optionally, purifying the latter. | 10-15-2015 |
20150231210 | Pharmaceutical Composition for Treating a Metabolic Syndrome - The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 08-20-2015 |
20150216981 | Stabilized Pharmaceutical Formulations of Insulin Analogues and/or Insulin Derivatives - Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed. | 08-06-2015 |
20150216941 | Stabilized Pharmaceutical Formulations of Insulin Analogues and/or Insulin Derivatives - Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed. | 08-06-2015 |
20150210755 | ANTI-POLY-N-ACETYL GLUCOSAMINE (PNAG) MONOCLONAL ANTIBODY AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF PNAG EXPRESSING BACTERIAL INFECTION - Provided are methods for the treatment or prevention of microbial infections (e.g., bacterial infection) in which the underlying pathology involves a PNAG-expressing microbe (e.g., PNAG-expressing bacteria). The methods of the invention generally involve administering to the subject an effective amount of an antibody that specifically binds to PNAG. Such methods are particularly useful for the treatment of nosocomial | 07-30-2015 |
20150208623 | TRANSGENIC NON-HUMAN ANIMAL AND USES THEREOF - The present invention relates generally to transgene constructs, transgenic non-human animals comprising transgene constructs, methods of making and methods of using the transgenic non-human animals comprising transgene constructs. An embodiment of the invention relates to methods of assaying the activation of GPCR ligands non-invasively in whole animals, tissue slices, or in native cells using a transgenic model containing a bioluminescent transgene reporter system that is responsive to pathway following ligand binding of GPCR receptors. | 07-30-2015 |
20150190475 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPART - Stabilized pharmaceutical formulations of insulin aspart are disclosed. | 07-09-2015 |
20150183780 | USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA - This invention is related to the use of inhibitors of vascular endothelial growth factor receptor 3 for treating hepatocellular carcinoma. | 07-02-2015 |
20150140607 | CHO EXPRESSION SYSTEM - The present invention is within the field of industrial protein production. The inventors have designed and constructed a new expression system comprising an expression vector coding for a glutamine synthetase of human or dog origin, and a CHO cell line. More specifically, the invention pertains to a combination of (i) a DNA vector suitable for production of a recombinant protein, wherein said vector comprises a sequence coding for a glutamine synthetase, and (ii) a Chinese Hamster Ovary (CHO) cell line, wherein said GS comprises a sequence at least 94.5% identical to the sequence of SEQ ID NO: 1 or to the sequence of SEQ ID NO: 2. | 05-21-2015 |
20150136639 | UNITARY PACKAGING FOR ONE CONTAINER FILLED WITH A LIQUID PHARMACEUTICAL PRODUCT - The invention provides a packaging for a container ( | 05-21-2015 |
20150111889 | Benzo[1,3]Dioxine Derivatives And Their Use As LPAR5 Antagonists - The present invention relates to compounds of the formula (I), wherein the residues A, R | 04-23-2015 |
20150111298 | Method for Producing Recombinant 11-De-O-Methyltomaymycin - The present invention provides a tomaymycin biosynthetic gene cluster of | 04-23-2015 |
20150099667 | METHODS FOR THE ACTIVATION OF SILENT GENES IN A MICROORGANISM - The present invention relates to a method for the activation of silent genes in microorganisms by co-cultivation of an inducer and a recipient microorganism. The inducer is selected from a chemical inducer, a microorganism inducer which is selected from a killed microorganism cell and/or inactivated culture medium in which said microorganism cell had been cultured and/or medium inducer. The present invention furthermore relates to a method for screening for an inducer and to a method of screening for a recipient microorganism by co-cultivation of an inducer and a recipient organism. The methods are useful for the detection of medicaments, such as antibiotics. The present invention further relates to media for culturing microorganisms comprising an inducer. | 04-09-2015 |
20150098939 | NOVEL ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF - The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used. | 04-09-2015 |
20150086601 | METHODS FOR PREVENTING BIOFILM FORMATION - Provided are methods for the treatment or prevention of microbial infections (e.g., nocosomial infection) in which the underlying pathology involves a PNAG-containing microbial bio film. The methods the invention generally involve administering to the subject an effective amount of an antibody that specifically binds to PNAG and disrupt or inhibit formation of PNAG-containing microbial bio films. Such methods are particularly useful for the treatment of nosocomial | 03-26-2015 |
20150065563 | USE OF VGII3 ACTIVITY MODULATOR FOR THE MODULATION OF ADIPOGENESIS - The present invention concerns Vgll3 a new target involved in adipogenesis modulation. | 03-05-2015 |
20150050270 | ANTIBODIES TO BRADYKININ B1 RECEPTOR LIGANDS - The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg | 02-19-2015 |
20150044197 | ANTIBODIES THAT SPECIFICALLY BIND TO THE EPHA2 RECEPTOR - The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate. | 02-12-2015 |
20150031902 | PROCESS FOR THE PREPARATION OF DRONEDARONE BY OXIDATION OF A SULPHENYL GROUP - The invention relates to a novel process for the preparation of dronedarone (I) and pharmaceutically acceptable salts thereof which comprises oxidizing a compound of formula (IV) or a salt thereof with an oxidizing agent in an organic or inorganic solvent or solvent mixture, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. Further aspects of the invention include the novel intermediary compound of formula (IV), and a process for the preparation thereof. | 01-29-2015 |
20150031901 | METHOD FOR PREPARING 5-AMINO-BENZOFURAN DERIVATIVES - The invention relates to a method for preparing 5-amino-benzoyl-benzofuran derivatives having the general formula in which R | 01-29-2015 |
20150018342 | Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals - The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example. | 01-15-2015 |
20140378686 | Indanyl-Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them - The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter. | 12-25-2014 |
20140378433 | PYRIMIDOOXAZOCINE DERIVATIVES AS MTOR - INHIBITORS - The invention relates to bicydic heterocyclic derivatives of general formula (I) to a process for preparing them and to the therapeutic use thereof. | 12-25-2014 |
20140357640 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula (I), (R2)n wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them. | 12-04-2014 |
20140349986 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF - The invention relates to substituted aminoindanes and analogs thereof of formula I | 11-27-2014 |
20140335102 | IN SILICO AFFINITY MATURATION - Methods are disclosed for increasing the binding affinity of binding proteins using in silico affinity maturation. | 11-13-2014 |
20140302053 | COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME - The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R) with a DMARD. | 10-09-2014 |
20140302012 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab - The invention provides a method for treating cancers including hematologic malignancies comprising administering a compound of Formula (I): in combination with one or both of bendamustine and rituximab. | 10-09-2014 |
20140296265 | Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR - The invention provides a method for treating cancers including hematologic malignancies comprising administering a compound of formula I: | 10-02-2014 |
20140296239 | Biaryl-propionic acid derivatives and their use as pharmaceuticals - The present invention relates to compounds of the formula I, | 10-02-2014 |
20140296233 | HETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 10-02-2014 |
20140288106 | CYCLOALKANE CARBOXYLIC ACID DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS - The present invention relates to compounds of formula 1 | 09-25-2014 |
20140288083 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula I, | 09-25-2014 |
20140286933 | STABLE IGG4 BASED BINDING AGENT FORMULATIONS - The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis. | 09-25-2014 |
20140275078 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING PI3KB INHIBITOR AND MAPK PATHWAY INHIBITOR, INCLUDING MEK AND RAF INHIBITORS - The present invention relates to compositions comprising at least one MAPK pathway inhibitor including MEK and RAF inhibitors and at least one PI3Kβ inhibitor, and also to uses thereof for the treatment of cancer. | 09-18-2014 |
20140275005 | SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides of formula (Ia) and formula (Ib). | 09-18-2014 |
20140271665 | Combinations of Kinase Inhibitors for the Treatment of Cancer - The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3. | 09-18-2014 |
20140259192 | TRANSGENIC ANIMAL COMPRISING A DELETION OR FUNCTIONAL DELETION OF THE 3'UTR OF AN ENDOGENOUS GENE - The present invention relates to the fields of knockout (KO) animal production. The invention is directed to a transgenic KO animal comprising a heterozygous or homozygous deletion or functional deletion of the gene's native 3′ untranslated region (3′UTR) at least in one of its endogenous gene loci, wherein the disrupted endogenous gene is transcribed into an m RNA without its native 3′UTR. Instead, a 3′UTR of choice, knocked in by the experimenter, is transcribed into an m RNA. The 3′UTR KO animals provide a new approach to study gene function as they enable to overexpress the gene products what are negatively regulated via their 3′UTR-s exclusively in those cells that already transcribe the gene, thereby avoiding the misexpression problem present in the animals produced by conventional transgenesis methods. The invention is further directed to KO animals, in which the gene with deletion of 3′UTR is GDNF, NGF or BDNF. | 09-11-2014 |
20140248280 | ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH PACLITAXEL FOR TREATMENT OF GYNECOLOGICAL CANCERS - Provided are methods and compositions for clinical treatment of advanced gynecological cancers using anti-ErbB3 antibodies combined with paclitaxel. | 09-04-2014 |
20140243328 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to compounds corresponding to formula (I): | 08-28-2014 |
20140243292 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, | 08-28-2014 |
20140235888 | (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID-(4'-TRIFLUORMETHYLPHENYL)-AMIDE TABLET FORMULATIONS WITH IMPROVED STABILITY - The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis. | 08-21-2014 |
20140235616 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to compounds corresponding to formula (I), in which R1, R2 and R3 are as defined in Claim | 08-21-2014 |
20140221656 | CRYSTALLINE SOLVATES OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE - The present invention relates to crystalline solvates of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride, processes for their preparation and the use thereof. | 08-07-2014 |
20140221285 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES - Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives are disclosed. | 08-07-2014 |
20140221281 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS - The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 08-07-2014 |
20140213513 | Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists - The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 07-31-2014 |
20140206760 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA - The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoaguability or fibrotic changes. | 07-24-2014 |
20140206611 | LONG-ACTING INSULIN FORMULATIONS - The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. | 07-24-2014 |
20140206609 | Functionalized Exendin-4 Derivatives - The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 07-24-2014 |
20140206608 | Exendin-4 Derivatives - The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 07-24-2014 |
20140199300 | COMBINATION THERAPY FOR THE TREATMENT OF CD19+ B-CELL MALIGNANCIES SYMPTOMS COMPRISING AN ANTI-CD1 MAYTANSINOID IMMUNOCONJUGATE AND RITUZIMAB - A combination of an anti-CD19 maytansinoid immunoconjugate and rituximab is used for treating CD19+CD20+ B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma. | 07-17-2014 |
20140194470 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF - The invention relates to compounds corresponding to formula (I), in the form of the base or of an acid-addition salt: | 07-10-2014 |
20140194445 | SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, | 07-10-2014 |
20140186885 | PROCESS FOR PREPARING GENETICALLY TRANSFORMED YEASTS CAPABLE OF PRODUCING A MOLECULE OF INTEREST AT A HIGH TITRE - The subject of the present invention is a process for preparing a genetically modified yeast by multicopy integration of at least four expression cassettes, allowing the production of a molecule of interest at high titre. The subject of the present invention is also yeasts transformed according to said process, and the use thereof for producing hydrocortisone. | 07-03-2014 |
20140186337 | Antitumors Combinations Containing Antibodies Recognizing Specifically CD38 And Bortezomib - Pharmaceutical composition comprising an antibody specifically recognizing CD38 and bortezomib. | 07-03-2014 |
20140178402 | PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9 - The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin/kexin type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. | 06-26-2014 |
20140162289 | IDENTIFYING MOLECULES MODULATING PROTEIN-PROTEIN INTERACTIONS USING PROTEASE ACTIVATED REPORTERS - Assay methods and systems use enzymatic cleavage resulting from protein-protein interaction to modulate (activate or inactivate) a reporter. | 06-12-2014 |
20140161819 | Compositions Comprising Anti-CD38 Antibodies and Lenalidomide - Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits. | 06-12-2014 |
20140154262 | HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS - The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. | 06-05-2014 |
20140148507 | PHARMACEUTICAL COMPOSITION AND SOLID GALENIC FORM HAVING A HIGH DRONEDARONE CONTENT, AND METHOD FOR PREPARING SAME - The present invention relates to pharmaceutical compositions to be used, in a solid galenic form, for oral administration, and primarily including dronedarone and/or at least one of the derivatives thereof, as well as to solid galenic forms manufactured as such from said compositions, preferably in the form of tablets or capsules. The present invention also relates to a method for preparing such solid galenic forms using a hot-melt process. | 05-29-2014 |
20140148494 | SPIRO-OXINDOLE MDM2 ANTAGONISTS - Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases. | 05-29-2014 |
20140142110 | KINASE INHIBITOR - The invention is directed to a compound of formula (I): | 05-22-2014 |
20140142023 | Pharmaceutical Composition for Treating A Metabolic Syndrome - The invention is directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. The invention is also directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one DPP-4 (dipeptidyl peptidase-4) inhibitor and optionally GLP-1R (glucagon-like peptide-1 receptor) agonist and/or at least one at least one anti-diabetic drug for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 05-22-2014 |
20140135328 | SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, | 05-15-2014 |
20140128616 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, wherein A, D, E, G, R | 05-08-2014 |
20140127802 | CONTROL OF CARBON DIOXIDE LEVELS AND PH IN SMALL VOLUME REACTORS - Strategies to control the level of dissolved carbon dioxide (CO | 05-08-2014 |
20140120609 | HUMIDITY CONTROL IN CHEMICAL REACTORS - Control of humidity in chemical reactors, and associated systems and methods, are generally described. In certain embodiments, the humidity within gas transport conduits and chambers can be controlled to inhibit unwanted condensation within gas transport pathways. By inhibiting condensation within gas transport pathways, clogging of such pathways can be limited (or eliminated) such that transport of gas can be more easily and controllably achieved. In addition, strategies for purging condensed liquid from chemical reactor systems are also described. | 05-01-2014 |
20140114081 | PROCESS FOR PREPARATION OF DRONEDARONE BY N-BUTYLATION - The invention relates to a novel process for preparation of dronedarone (I) and pharmaceutically acceptable salts thereof where the compound of formula (II) or salt thereof is reacted with a compound of formula L-(CH | 04-24-2014 |
20140106366 | METHODS FOR DETERMINING SODIUM-PROTON-EXCHANGER LIGAND EFFICIENCY - The present invention relates to methods for determining the efficiency of an ion channel ligand comprising (a) contacting a cell expressing the ion channel with (i) plasma of an animal and (ii) the ion channel ligand and (b) determining the effect of the ion channel ligand on the cell. | 04-17-2014 |
20140105890 | HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLAR FORM OF THE BETA-AMYLOID PEPTIDE - The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease. | 04-17-2014 |
20140100156 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS - The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 04-10-2014 |
20140099333 | PYRROLIDINONE DERIVATIVES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS - The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them. | 04-10-2014 |
20140094488 | 2-AMINO-3-(IMIDAZOL-2-YL)-PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS VEGF RECEPTOR KINASE INHIBITORS - The invention relates to the compounds of general formula (I): Preparation process and therapeutic use. | 04-03-2014 |
20140094450 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES AS APJ RECEPTOR MODULATORS - The present invention relates to benzoimidazole-carboxylic acid amide compounds of the formula I, | 04-03-2014 |
20140094429 | FGF RECEPTOR-ACTIVATING 3-O-ALKYL OLIGOSACCHARIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The invention relates to the FGF receptor-activating oligosaccharides corresponding to formula (I): | 04-03-2014 |
20140088189 | METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / BETA-BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION - The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a beta-blockers treatment, by performing the following steps:
| 03-27-2014 |
20140088158 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, | 03-27-2014 |
20140088077 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS - The invention relates to substituted tetrahydronaphthalenes and derivatives thereof, and also to the physiologically compatible salts and physiologically functional derivatives thereof, to preparation thereof, to medicaments comprising at least one inventive substituted tetrahydronaphthalene or derivative thereof, and to the use of the inventive substituted tetrahydronaphthalenes and derivatives thereof as medicaments. | 03-27-2014 |
20140081213 | SAFETY ASSEMBLY FOR A SYRINGE - A safety support device for a syringe comprises a support sheath for the body of the syringe and an inner sheath suitable for sliding relative to the support sheath between a waiting, retracted position and the extended position for protecting the needle of the syringe. The device has means for holding the syringe body relative to the support sheath and retaining means suitable for being activated to retain g the inner sheath in the waiting, retracted position inside the support sheath and for being deactivated by the piston of the syringe to allow the inner sheath to extend into its protective, extended position. | 03-20-2014 |
20140081035 | PROCESS FOR PREPARATION OF DRONEDARONE BY MESYLATION - The invention relates to a novel process for preparation of N-[2-n-butyl-3-[4-[3-(di-n-butylamino)-propoxy]-benzoyl]-benzofuran-5-yl]methanesulfonamide (I) and pharmaceutical acceptable salts thereof, where a salt of (5-amino-2-butyl-1-benzofuran-3-yl) {4-[3-(di-n-butylamino)propoxy]phenyl}methanone of formula (II)—where A is a mono- or dibasic acid forming an acid addition salt with the compound of formula (II), n is 1 if A is dibasic acid and n is 1 or 2 if A is a monobasic acid—is reacted with a mesylating reagent in a heterogen reaction, if desired, in the presence of a phase transfer catalyst. The invention also relates to the novel salts of compound of formula (II), for the preparation thereof and their use in the preparation of dronedarone. | 03-20-2014 |
20140081019 | PROCESS FOR THE PREPARATION OF DEUTERATED COMPOUNDS CONTAINING N-ALKYL GROUPS - The present invention relates to a process for deuteration of amines in the alpha and/or beta position of the N-atom by using a deuterium source and a Ruthenium(II) based catalyst. | 03-20-2014 |
20140073662 | Spirocyclic nitriles as protease inhibitors - The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments. | 03-13-2014 |
20140073563 | FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME - The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas. | 03-13-2014 |
20140072587 | USE OF ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE ANTIBODY FOR THE TREATMENT OF B-CELL MALIGNANCIES SYMPTOMS - An anti-CD19 maytansinoid immunoconjugate is used for treating B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma. | 03-13-2014 |
20140069914 | EXPANDABLE SAMPLE TRAY AND STORAGE SYSTEM - Described is a sample tray comprising a first sidewall, a first rearwall section coupled to the first sidewall, a first base section coupled to the first sidewall, the first base section disposed approximately perpendicular to the first sidewall, a second sidewall, a second rearwall section coupled to the second sidewall, and a second base section coupled to the second sidewall, the second base section disposed approximately perpendicular to the second sidewall. The first rearwall section is telescopically coupled to the second rearwall section, and the first base section is telescopically coupled to the second base section. | 03-13-2014 |
20140066437 | OXATHIAZINE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL OR HETEROMETHYLENE GROUPS, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF - The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia. | 03-06-2014 |
20140065649 | TEST SYSTEMS AND METHODS FOR IDENTIFYING AND CHARACTERISING LIPID LOWERING DRUGS - The present invention relates to methods for the identification and characterization of therapeutic candidates for use in the treatment of a disease or condition associated with elevated LDL-C levels involving a rodent, methods for the testing of the efficacy of an antibody specifically binding to proprotein convertase subtilisin/kexin type 9 (PCSK9) involving a rodent, as well as a rodent and its use in the identification or profiling of compounds for modulation of a disease or condition associated with elevated LDL-C levels. | 03-06-2014 |
20140056920 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST - The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody. | 02-27-2014 |
20140056895 | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation - The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins. | 02-27-2014 |
20140051642 | COMPOSITION COMPRISING AFLIBERCEPT, FOLINIC ACID, 5-FLUOROURACIL (5-FU) AND IRINOCETAN (FOLFIRI) - Pharmaceutical composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI) useful in the treatment of Colorectal cancer (CRC). | 02-20-2014 |
20140046078 | PROCESS FOR SYNTHESIZING KETO BENZOFURAN DERIVATIVES - The invention relates to a method for synthesizing benzofuran derivatives, in particular the dronedarone of formula (D), including carrying out a Fries rearrangement reaction using a sulfonamido-benzofuran ester intermediate. | 02-13-2014 |
20140046032 | METHOD OF PRODUCTION OF SIALYLATED ANTIBODIES - The present invention relates to a method for producing an IgG antibody, wherein at least 80% of the said antibody comprises a complex, bi-antennary oligosaccharide, which contains two sialic acid residues, attached to the Fc domain of the antibody. The said method comprises the steps of introducing a mutation in the Fc domain of the antibody, and expressing the mutant antibody in a cell which expresses a galactosyltransferase and a sialyltransferase activity. | 02-13-2014 |
20140039011 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA - The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes. | 02-06-2014 |
20140038946 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS - The disclosure relates to (heterocycle-fused piperidine)-(piperazinyl)-1-alkanone derivatives and (heterocycle-fused pyrrolidine)-(piperazinyl)-1-alkanone derivatives of formula (I): | 02-06-2014 |
20140031762 | NEEDLE SHEATHING DEVICE WITH FLEXIBLE END-PIECE FOR SYRINGE - The invention relates to a safe support device for a syringe, said support comprising a support sheath for the body of a syringe, and safety means which comprise an inner sheath suitable for sliding relative to said support sheath between a waiting retracted position, in which said inner sheath is substantially retracted inside said support sheath, and an active protection position, in which said inner sheath projects from said support sheath. The inner sheath has a free end portion formed by a flexible end-piece. The invention also relates to an assembly comprising such a safe support device and a syringe having a body, a piston and a needle disposed at one end of said body. | 01-30-2014 |
20140031316 | POLYSACCHARIDES COMPRISING TWO ANTITHROMBIN III-BINDING SITES, PREPARATION THEREOF AND USE THEREOF AS ANTITHROMBOTIC MEDICAMENTS - The invention relates to sulphated polysaccharides which have the general structure of the constituent polysaccharides of heparin and which have a molecular weight of less than 8000 Daltons, comprising two antithrombin III-binding hexasaccharide sequences corresponding to formula (I) in which: R1 represents an OH group when the hexasaccharide of formula (I) is located at the reducing end of the polysaccharide, or else R1 represents a bond with another saccharide unit of said polysaccharide; R2 represents a hydrogen atom when the hexasaccharide of formula (I) is located at the non-reducing end of the polysaccharide, in which case the bond between carbon atoms 4 and 5 of the first saccharide unit of said hexasaccharide is a double bond, or else R2 represents a bond with another saccharide unit of said polysaccharide, in which case the bond between carbon atoms 4 and 5 of the first saccharide unit is a single bond. Preparation thereof, use thereof as antithrombotic medicaments, and also use thereof in a method for analysing a sample of a heparin derivative. | 01-30-2014 |
20140030819 | NANOPILLAR FIELD-EFFECT AND JUNCTION TRANSISTORS WITH FUNCTIONALIZED GATE AND BASE ELECTRODES - Systems and methods for molecular sensing are described. Molecular sensors are described which are based on field-effect or bipolar junction transistors. These transistors have a nanopillar with a functionalized layer contacted to either the base or the gate electrode. The functional layer can bind molecules, which causes an electrical signal in the sensor. | 01-30-2014 |
20140024684 | BENZOIC ACID SALT OF OTAMIXABAN - The invention relates to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate, and to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate which is in a crystalline form or in at least partially crystalline form, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa. | 01-23-2014 |
20140024653 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING PI3K INHIBITOR AND MEK INHIBITOR - Methods of treating patients with cancer are provided, wherein the methods comprise administering to the patient an effective amount of a MEK inhibitor and an effective amount of a PI3K inhibitor. Compositions in which the MEK and PI3K inhibitors are combined also are described. | 01-23-2014 |
20140024584 | TETRASUBSTITUTED OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF - The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia. | 01-23-2014 |
20140023649 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 01-23-2014 |
20140018554 | REDUCTIVE AMINATION PROCESS FOR PREPARATION OF DRONEDARONE USING AMINE INTERMEDIARY COMPOUND - The invention relates to a novel process for preparation of drohedarone of formula (I) and pharmaceutically acceptable salts thereof characterized in that a compound of formula (II) is reacted in the presence of a reductive agent with butyraldehyde and/or butanoic acid, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. The invention also relates to some hovel intermediary compounds and the preparation thereof. | 01-16-2014 |
20140018553 | PROCESS FOR SYNTHESIZING KETO-BENZOFURAN DERIVATIVES | 01-16-2014 |
20140018398 | OTAMIXABAN FORMULATIONS WITH IMPROVED STABILITY - The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa. | 01-16-2014 |
20140011734 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION - The present invention relates to compounds of the Formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, X1, X2, X3 and X4 have the meanings indicated in the claims, and which are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb), and are suitable, for example, for the therapy and prophylaxis of athero-thrombotic diseases. The invention furthermore relates to processes for the preparation of compounds of the Formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them. | 01-09-2014 |
20140005392 | METHOD FOR PRODUCING 2-(2-AMINOPYRIMIDIN-4-YL)-1H-INDOLE-5-CARBOXYLIC ACID DERIVATIVES | 01-02-2014 |
20140005189 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS | 01-02-2014 |
20140004106 | STABLE IGG4 BASED BINDING AGENT FORMULATIONS | 01-02-2014 |
20140001077 | PACKAGING FOR UNIT PHARMACEUTICAL PRODUCTS | 01-02-2014 |
20130345404 | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation - The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins. | 12-26-2013 |
20130345207 | BENZYL-OXATHIAZINE DERIVATIVES SUBSTITUTED WITH ADAMANTANE AND NORADAMANTANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF - The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia. | 12-26-2013 |
20130345128 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF - The invention relates to the compounds of formula (I) and physiologically acceptable salts thereof. The compounds are suitable, e.g., for treating hyperglycemia. | 12-26-2013 |
20130345127 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF - The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia. | 12-26-2013 |
20130345126 | BRANCHED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF - The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia. | 12-26-2013 |
20130345125 | DI- AND TRI-SUBSTITUTED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF - The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia. | 12-26-2013 |
20130344074 | USES OF A DUAL V REGION ANTIBODY-LIKE PROTEIN - Uses of a dual V region antibody-like protein or a fragment of a dual V region antibody-like region. | 12-26-2013 |
20130338150 | DI AND TRI - SUBSTITUTED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF - The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia. | 12-19-2013 |
20130338066 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF - The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia. | 12-19-2013 |
20130336893 | Exedin-4 Peptide Analogues - The present invention relates to exendin-4 peptide analogues and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. | 12-19-2013 |
20130330341 | SINGLE NUCLEOTIDE POLYMORPHISMS IN THE PROMOTER OF VEGFA GENE AND THEIR USE AS PREDICTIVE MARKERS FOR ANTI-VEGF TREATMENTS - The invention relates to the treatment and the diagnosis of a group of patients bearing specific alleles of single nucleotide polymorphisms in the promoter region of the VEGFA gene. These patients are more responsive to Aflibercept and more likely to be efficiently treated by anti-VEGF therapy. | 12-12-2013 |
20130316965 | IDRABIOTAPARINUX FOR THE TREATMENT OF PULMONARY EMBOLISM AND FOR THE SECONDARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS - The invention relates to idrabiotaparinux for use in the treatment of pulmonary embolism in patients with or without deep venous thrombosis and for the secondary prevention of venous thromboembolic events in said patients, wherein the efficacy and safety of said uses are clinically proven by a phase III clinical trial. | 11-28-2013 |
20130315913 | ANTI-LIGHT ANTIBODY THERAPY FOR INFLAMMATORY BOWEL DISEASE - The present invention provides safe therapeutic doses of an antagonist of human LIGHT (lymphotoxin-like, exhibits inducible expression and competes with Herpes Virus Glycoprotein D for Herpes Virus Entry Mediator (HVEM), a receptor expressed by T lymphocytes), as well as methods of monitoring whether a therapeutic dose of an anti-LIGHT antagonist is safe. | 11-28-2013 |
20130289031 | PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF - The invention relates to novel products of formula (Ia) or (Ib): | 10-31-2013 |
20130274253 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS - The present invention relates to novel chemical compounds derived from pyrimidines, to the method for preparing same, to the novel intermediates obtained, to the use thereof as drugs, to the pharmaceutical compositions containing same, and to the therapeutic use thereof as AKT inhibitors. | 10-17-2013 |
20130274120 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Ms4a6d nucleic acid or Ms4a6d protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 10-17-2013 |
20130273049 | ROBO1-FC FUSION PROTEIN FOR USE IN THE TREATMENT OF HEPATOCARCINOMA - The present invention relates to the use a Robo1-Fc recombinant protein for treating cancer, in particular hepatocarcinoma. | 10-17-2013 |
20130261106 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF - The present invention relates to compounds of formula (I): | 10-03-2013 |
20130259866 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 10-03-2013 |
20130252974 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS - The present invention relates to 5,6-bisaryl-2-pyridinecarboxamides, to their preparation and to their therapeutic use as urotensin II receptor antagonists. | 09-26-2013 |
20130251794 | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same - The present invention relates to a method for “hot melt coating” of pharmaceutical active ingredients characterized by organoleptic or physicochemical properties that it is desirable to mask. | 09-26-2013 |
20130251718 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-26-2013 |
20130251717 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-26-2013 |
20130251716 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-26-2013 |
20130251714 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use - The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders. | 09-26-2013 |
20130251667 | AMIDE DENDRIMER COMPOSITIONS - Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester. | 09-26-2013 |
20130246035 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use - The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders. | 09-19-2013 |
20130245274 | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives - The present invention relates to a process for the preparation of a compound of the formula I, | 09-19-2013 |
20130245115 | PHARMACEUTICAL COMPOSITION AND DOSAGE FORM COMPRISING DRONEDARONE, AND PREPARATION METHOD THEREOF - The disclosure relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in unit dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal time effect following oral administration in humans. The lipid carrier allows: the solubilization of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent. | 09-19-2013 |
20130245023 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF - The invention relates to the 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine derivatives corresponding to general formula (I): | 09-19-2013 |
20130245008 | NITROBENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF - The invention relates to the nitrobenzothiazole derivatives of general formula (I): and to the use thereof for treating tuberculosis. | 09-19-2013 |
20130245006 | NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF - The invention relates to indolizine derivatives of general formula (I), where A, B, m, W, n and R2 are as defined in claim | 09-19-2013 |
20130244002 | MARKED SOLID PHARMACEUTICAL FORM, AND METHOD FOR THE PRODUCTION THEREOF BY MEANS OF LASER MARKING - The invention relates to a marked solid pharmaceutical form including a continuous groove on the surface thereof, said groove preferably being 20 μm to 50 μm deep and preferably 5 μm to 120 μm wide. The invention also relates to a method for marking such a pharmaceutical form by forming at least one groove therein by means of laser ablation of the surface of the solid form, said method being such that the laser ablation is carried out with laser energy of 0.1 to 500 mJ/mm | 09-19-2013 |
20130243783 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use - The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders. | 09-19-2013 |
20130243778 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-19-2013 |
20130243777 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-19-2013 |
20130243776 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-19-2013 |
20130243719 | POLYMERIC CONJUGATES OF ACTIVE PRINCIPLES, THEIR PROCESS OF PREPARATION AND THEIR POLYMERIC INTERMEDIATES - The present invention relates to novel conjugates of active principles grafted to a polymer, to the nanoparticles comprising them, to their preparation and to their polymeric intermediates. | 09-19-2013 |
20130237513 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY - The invention relates to azetidine derivatives having the formula (I): | 09-12-2013 |
20130236476 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use - The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders. | 09-12-2013 |
20130236463 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-12-2013 |
20130236462 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-12-2013 |
20130236461 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-12-2013 |
20130236460 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 09-12-2013 |
20130231388 | (CARBOXYLALKYLENEPHENYL)PHENYLOXAMIDES, METHOD FOR THE PRODUCTION THEREOF AND USE OF SAME AS A MEDICAMENT - The invention relates to (carboxylalkylenephenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament. | 09-05-2013 |
20130225605 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS - The present invention relates to compounds of the formula I, | 08-29-2013 |
20130217763 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY - Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. | 08-22-2013 |
20130211087 | 7-AZA-SPIRO[3,5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The present invention is directed to 7-aza-spiro[3.5]nonane-7-carboxylate derivatives of the Formula I. The compounds of the invention are inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The invention also relates to processes for the preparation of compounds of the Formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them. | 08-15-2013 |
20130211085 | PROCESS FOR THE PREPARATION OF ENANTIOMERIC FORMS OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES - The disclosure relates to a process for the preparation of the enantiomeric forms of 2,3-diaminopropionic acid derivatives of formula I, | 08-15-2013 |
20130209469 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 08-15-2013 |
20130203651 | PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME - The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 08-08-2013 |
20130198182 | METHOD, SYSTEM AND PROGRAM FOR COMPARING CLAIMED ANTIBODIES WITH A TARGET ANTIBODY - A method, system and program for facilitating consideration of clearance of a target sequence. The method comprises retrieving a predefined patent document library data structure having fields for claim identifiers, a matching criterion for a comparison, translated claim statements, matching procedures, sequence identifiers, logical relationships between claim statements and machine readable comparison instructions; retrieving a sequence database indexed by sequence identifier, comparing the target sequence with each of the claims in the retrieved patent document library data structure, using a corresponding machine readable comparison instructions and a sequence which is obtained from the retrieved sequence database corresponding to a sequence identified in the claim and determining whether each of claims in the retrieved patent document library data structure matches the target sequence based upon a result of the comparison. Each predefined patent document library data structure can be user customized for each claim. | 08-01-2013 |
20130197080 | USE OF TERIFLUNOMIDE FOR TREATING MULTIPLE SCLEROSIS - This invention relates to use of teriflunomide for treating Multiple Sclerosis (MS) and managing the risks associated with the use of teriflunomide. | 08-01-2013 |
20130190268 | BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY - The invention relates to novel polysaccharides with an antithrombotic activity, having at least one covalent bond with biotin or a biotin derivative, wherein said covalent bond is resistant to metabolic cleavage and comprises a linkage X selected from the group consisting of —O—, —N(R)—, —N(R)—CO— and —N(R′)—CO—N(R″)—, wherein R is an alkyl group and R′ and R″, which may be identical or different, are, independently of one another, a hydrogen atom or alkyl group. | 07-25-2013 |
20130189714 | METHOD FOR THE DETECTION AND/OR QUANTIFICATION OF THE INTERACTION OF PLATELETS WITH INTERACTION PARTNERS - The invention refers to methods for detecting and/or quantifying the interaction of platelets or platelet surface molecules with an interaction partner, methods for detecting and/or quantifying the capability of a test substance to modulate the interaction of platelets or platelet surface molecules with interaction partners and articles or manufacture. | 07-25-2013 |
20130183382 | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same - The present invention relates to fexofenadine granules, to a composition containing them and to a process for the hot-melt coating of fexofenadine. The process for the hot-melt coating of fexofenadine allows efficient masking of its bitter taste without, however, unacceptably slowing down its dissolution. | 07-18-2013 |
20130178472 | ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF - The invention relates to pyridine-pyridinone derivatives general formula (I): | 07-11-2013 |
20130171731 | REVERSIBLY IMMORTALIZED CELLS AS WELL AS METHODS RELATING HERETO - The present invention relates to methods of producing a reversibly immortalized cell, cells obtainable by the above method, eukaryotic cells comprising one or more nucleic acid(s) coding for one or more immortalizing protein(s) and methods of re-differentiating these cells. | 07-04-2013 |
20130165675 | PROCESS FOR PREPARING AMINOBENZOYLBENZOFURAN DERIVATIVES - The disclosure relates to a process for preparing 5-aminobenzoylbenzofuran derivatives of formula I: | 06-27-2013 |
20130165674 | PROCESS FOR PREPARING BENZOFURAN DERIVATIVES SUBSTITUTED AT POSITION 5 - The disclosure relates to a process for preparing benzofuran derivatives of general formula I: | 06-27-2013 |
20130165673 | METHOD FOR PREPARING 3-KETO-BENZOFURANE DERIVATIVES - The invention relates to a method for preparing 3-keto-benzofurane derivatives of the general formula: Formula (I), where R is an alkyl or aryl group, R | 06-27-2013 |
20130165422 | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - The disclosure relates to hexafluoroisopropyl carbamate derivatives of general formula (I): | 06-27-2013 |
20130158051 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING - The invention relates to oxazolopyrimidine compounds of formula (I), where A, R | 06-20-2013 |
20130157941 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES - The present invention relates to azolopyridin-3-one derivatives of the general formula (I) with the meanings specified in the description, to their pharmaceutically usable salts and to their use as drug substances. | 06-20-2013 |
20130157890 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Ctla2b nucleic acid or Ctla2b protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 06-20-2013 |
20130157880 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND INVOLVED IN PAIN AS WELL AS METHODS OF DIAGNOSING ALGESIA - The present invention relates to a method of identifying a compound involved in pain, the use of Car3 nucleic acid or Car3 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same. | 06-20-2013 |
20130156786 | PEPTIDE OR PEPTIDE COMPLEX BINDING TO 2 INTEGRIN AND METHODS AND USES INVOLVING THE SAME - The present invention relates to a peptide or peptide complex binding to α2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting α2 integrin and a screening method. | 06-20-2013 |
20130150340 | 6-(4-Hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors - The present invention relates to 1H-pyrazolo[3,4-b]pyridine compounds of the formula I, | 06-13-2013 |
20130149310 | COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME - The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). | 06-13-2013 |
20130137718 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N--1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE - Industrially applicable process for preparing 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, and salts thereof. | 05-30-2013 |
20130137691 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS - The invention relates to compounds of formula (I): | 05-30-2013 |
20130137685 | 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES - The invention relates to oxazolopyrimidine compounds of formula (I), where A, R | 05-30-2013 |
20130137659 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - Provided herein are compounds of formula (I): | 05-30-2013 |
20130131358 | Novel Process for the Preparation of Dronedarone - The subject of the invention is a novel process for the preparation of N-[2-n-butyl-3-{4-[(3-di-n-butylamino)-propoxy]benzoyl}benzofuran-5-yl]-methanesulfonamide of formula I: | 05-23-2013 |
20130131034 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS - The instant invention relates to derivatives of formula (I) | 05-23-2013 |
20130123288 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF - Compounds of formula (I): | 05-16-2013 |
20130123143 | METHOD FOR IDENTIFYING A COMPOUND HAVING AN ANTIARRHYTHMIC EFFECT AS WELL AS USES RELATING THERETO - The present invention relates to a method of identifying a compound having an antiarrhythmic effect and to a use of adenosine-diphospho-ribose cyclase (cardiac ADPRC) for the identification of a compound having said effect. | 05-16-2013 |
20130122113 | ANTITUMORAL COMBINATION COMPRISING OMBRABULIN, A TAXANE DERIVATIVE AND A PLATINUM DERIVATIVE - The invention concerns an antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative and its use in the treatment of advanced solid tumors. | 05-16-2013 |